2458202-06-5
2458202-06-5
Chemical Structure
Biological Activity: Vilamakitug (XB-2001) is an anti-IL-1α monoclonal antibody that blocks IL-1α signaling. Vilamakitug binds to and neutralizes IL-1α. Vilamakitug can be used for research on metastatic colorectal cancer and melanoma[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Vilamakitug | 95.45% | Vilamakitug (XB-2001) is an anti-IL-1α monoclonal antibody that blocks IL-1α signaling. Vilamakitug binds to and neutralizes IL-1α. Vilamakitug can be used for research on metastatic colorectal cancer and melanoma. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Mei HR, et al. The therapeutic potential of targeting IL-1α signaling pathways in a mouse model of pulmonary melanoma. Sci Rep. 2026;16(1):13452.
- [2]. Thibaudin M, et al. Safety and efficacy of trifluridine/tipiracil +/- bevacizumab plus XB2001 (anti-IL-1α antibody): a single-center phase 1 trial. Signal transduction and targeted therapy. 2025 Jan 17;10(1):22.
